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Background: Many inborn errors of metabolism (IEM) may present as sudden infant death 44 
(SID). Nowadays increasing numbers of patients with an IEM are identified 45 
presymptomatically by population neonatal screening (NBS) programs. However, some 46 
patients escape early detection because their symptoms and signs start before NBS test results 47 
become available, die even before the sample for NBS has been drawn, or due to IEMs which 48 
are not included in the NBS programs.  49 
Objectives & methods: A comprehensive systematic literature review to identify all IEMs 50 
associated with SID, including their treatability and detectability by NBS technologies. Reye 51 
syndrome (RS) was included in the search strategy because this condition can be considered 52 
as a possible pre-stage of SID in a continuum of aggravating symptoms.  53 
Results: 43 IEMs were identified that were associated with SID and/or RS. Of these IEMs (a) 54 
26 can already present during the neonatal period, (b) treatment is available for at least 32, 55 
and (c) 26 can currently be identified by analysis of acylcarnitines and amino acids in dried 56 
bloodspots.  57 
Conclusion: We advocate extensive analysis of amino acids and acylcarnitines in 58 
blood/plasma/dried bloodspots and urine for all children who died suddenly and/or 59 
unexpectedly, including neonates in whom a blood spot for the routine NBS program has not 60 
yet been drawn. The application of combined metabolite screening and DNA sequencing 61 
techniques would facilitate fast identification and maximal diagnostic yield. This is important 62 
information for both clinicians who need to maintain clinical awareness, and for decision-63 





Many inborn errors of metabolism (IEM) that cause cellular energy deficiency and/or 67 
intoxication are associated with sudden infant death (SID). Based on retrospective studies, 68 
approximately 0.9-6% of all SID cases represent IEMs.[1-3] Although these studies were 69 
subject to several forms of selection bias, they form the rationale behind metabolic autopsy 70 
protocols for young children, which include analyses of amino acid and acylcarnitine profiles 71 
in plasma/urine.[4]  72 
Since the 1990s, tandem mass spectrometry (TMS) in dried blood spots (DBS) has 73 
been developed to perform high-throughput simultaneous quantitative analysis of different 74 
diagnostic metabolites in small amounts in biological samples.[5] As a consequence, in the 75 
last two decades population neonatal bloodspot screening (NBS) programs have been 76 
expanded with many IEMs. Patients with treatable IEMs can remain undetected by population 77 
NBS programs for several reasons. In some IEMs, symptoms and signs including death 78 
already occur prior to the NBS test results becoming available or even before the blood spot 79 
has been drawn, annulling the benefits of NBS.[6-10] This is especially relevant in areas 80 
where neonatal blood is collected relatively late, for instance in the Netherlands (i.e. 72-168 81 
hours after birth).[11, 12] Between different areas worldwide, population NBS programs 82 
differ with respect to methodological aspects and disorders to screen for.  83 
Systematic studies on the percentage of IEMs among SID cases are required as, 84 
although rare, preventable SID cases due to treatable IEMs still occur. Therefore, we 85 
performed this comprehensive systematic literature review to identify IEMs (1) that are 86 
associated with SID, (2) have clinical ascertainment during the neonatal period, (3) are 87 





Search strategy 91 
A literature search for relevant references was performed according to the Cochrane 92 
Collaboration methodology. CINAHL, Cochrane, Pubmed and Embase public databases were 93 
searched using both Medical Subject Headings (MeSH) terms and free text. A detailed 94 
presentation and assessment of the search strategy, including the Preferred Reporting Items 95 
for Systematic review and Meta-Analysis Protocols (PRISMA-P) 2015 checklist, is presented 96 
in Supplemental Data 1. Figure 1 presents the flowchart of the detailed search strategy 97 
together with the steps of the systematic review.  98 
The following search terms were included to further optimize our search strategy. The 99 
term “mitochondrial fatty acid oxidation” was included because, based on previous studies 100 
and our personal expertise, this disease group has the highest incidence among IEMs 101 
associated with both SID [1-3] and NBS programs.[6, 7, 10] SID is historically defined to 102 
occur in the first year of life. We therefore expanded our search strategy with “sudden 103 
unexpected death of infant”. Originally, Reye syndrome (RS) has been described as a non-104 
inflammatory encephalopathy in childhood, associated with hepatic dysfunction.[13] Since 105 
the 1980s it has been recognized as a presenting symptom of IEMs rather than being an 106 
etiologic diagnosis.[14] We considered RS as a potential pre-stage of SID in a continuum of 107 
aggravating symptoms. Therefore we also included the term “Reye syndrome” in our search 108 
strategy.  109 
All reports published since 1990 were included, corresponding with the first 110 
publications about the availability of TMS and general progressions made in the field of 111 
molecular and enzymatic confirmatory testing in the field of IEMs. References published 112 
before 1990 were only included when available upon request. Two independent reviewers 113 
(GK and TD) performed title and abstract screenings. Consensus on inclusion was reached 114 
6 
 
during regular meetings. Subsequently, three independent (WvR, GK and TD) screened the 115 
full text articles of all selected references. The inclusion of a diagnosis as a cause of SID 116 
and/or RS was based on the presence of detailed patient data and a confirmed diagnosis in the 117 
full text articles. Specific exclusion criteria were (1) no detailed patient data reported; (2) lack 118 
of accessibility of the articles; (3) confirmatory metabolite, molecular or enzymatic studies 119 
were inconclusive; (4) when there had been a (possible) additionally contributing cause of 120 
death; (5) patients suffering from SID and/or RS aged above 18 years and/or (6) abstract 121 
and/or article not available in English or Dutch language. 122 
 123 
Data analysis 124 
All IEMs were classified according to the Society for the Study of Inborn Errors of 125 
Metabolism classification of IEMs.[15] Based on the included references, associations 126 
between confirmed diagnoses and SID and/or RS were documented. For example, a plus sign 127 
in the SID column in Table 1 indicates that the particular IEM has been associated with SID 128 
in at least one of the corresponding references presented in Supplemental Table 1. Neonatal 129 
clinical presentation was reported based on detailed patient data of the included references. 130 
Based on recent textbooks and literature, treatability [16] and detectability by TMS in a DBS 131 





This systematic review included a total of 136 references. Table 1 presents the 43 IEMs 135 
associated with either SID and/or RS, concerning mostly disorders of mitochondrial fatty acid 136 
oxidation, the urea cycle and organic acidurias. References of all included articles are 137 
presented in Supplemental Table 1. Out of these 43 IEMs, minimally 26 already presented 138 
during the neonatal period of which 15 are both treatable and detectable by TMS 139 
methodologies. In at least 32 out of the 43 IEMs, a specific dietary and/or pharmacological 140 
treatment is available in order to prevent clinical presentation. Identification by population 141 
NBS programs by TMS analysis of amino acids and/or acylcarnitines in DBS is possible in 26 142 





This unique systematic literature review identified at least 43 IEMs that are associated with 146 
SID and/or RS, of which 26 can already present during the neonatal period. At least 32 out of 147 
43 are considered as treatable disorders and 26 out of 43 are currently detectable by TMS 148 
analysis of amino acids and/or acylcarnitines in DBS. The remaining 17 IEMs will not be 149 
detected by current metabolite screening methods, but require additional testing either by 150 
expanding the metabolic testing options or by genetic and/or enzymatic laboratory methods. 151 
Out of the 26 IEMs in which clinical ascertainment within the neonatal period has been 152 
reported, at least 15 are both treatable and detectable by TMS analysis. This is important 153 
information to improve population NBS programs as early detection and subsequent treatment 154 
may prevent clinical presentation and even death (Table 1). Moreover, with the results of our 155 
study, diagnostic (laboratory) protocols can be improved for children (including neonates) 156 
presenting with sudden/unexpected death. 157 
There is no doubt that expanded population NBS programs have significantly 158 
improved the outcomes of many patients, but there remains a subset of patients that 159 
unfortunately escapes early identification.[20] First, one group escapes early identification 160 
because limited numbers of IEMs are included in the NBS programs. It is important to realize 161 
that population NBS programs differ worldwide, and may even differ within countries. 162 
Second, another group escapes early identification because symptoms and signs present 163 
before NBS test results become available or even before the blood spot has been drawn. This 164 
is aggravated by relative late NBS blood obtainment and/or follow-up after positive test 165 
results in some areas/countries. In the Netherlands neonatal blood for the NBS test is collected 166 
between 72-168 hours after birth.[11, 12] In 2013, the response rate for the NBS program was 167 
99.35%. Referral to a metabolic physician was initiated before day 8 in 62% of the positive 168 
neonates, whereas 441 out of 173,118 newborns died (etiology not specified) before the NBS 169 
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blood spot could be drawn.[11] Reports from population NBS programs from Australia, the 170 
USA and Germany present patients with clinical ascertainment and sometimes even neonatal 171 
death before NBS test results have become available (indicated with ** in table 1).[6, 7, 10] 172 
In line with these reports, in our country since the expansion of the NBS program (Table 1), 173 
clinical symptoms and signs preceded the NBS test results, sometimes even leading to early 174 
death, in cases of very long-chain acyl-CoA dehydrogenase deficiency, long-chain 3-175 
hydroxyacyl-CoA dehydrogenase deficiency/mitochondrial trifunctional protein deficiency, 176 
medium-chain acyl-CoA dehydrogenase deficiency, maple syrup urine disease and 177 
galactosemia (data unpublished). Last, patients may escape early identification due to false-178 
negative NBS results, (for example patients with carnitine transporter deficiency or very long-179 
chain acyl-CoA dehydrogenase deficiency [21, 22]) or (pre-)analytical reasons, which is of 180 
concern for patients with carnitine palmitoyltransferase 2 deficiency [23]. These examples stir 181 
the debate on whether the NBS test should be performed earlier in life and/or twice at two 182 
different timings. 183 
The general view on ‘the metabolic autopsy’ has originated from case studies and 184 
small retrospective cohort studies that introduced bias.[4] It is generally recognized that low 185 
incidences and aspecific symptoms and signs cause underdiagnosis of IEMs.[9] The current 186 
study strengthens the rationale why – despite low incidences of the individual IEMs – 187 
neonates who died deserve at least a TMS analysis of amino acids and acylcarnitines in a 188 
DBS, when feasible. For most of the disorders listed in Table 1, the associated recurrence rate 189 
for affected families is at least 25%.  190 
Several methodological issues of this study should be mentioned. First, the 191 
retrospective study designs of many included cohort studies and case studies could have 192 
introduced both a publication bias and a data availability bias as 1) reports do not always 193 
describe detailed patient data and 2) obviously not all SID cases due to IEMs have been 194 
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reported in literature. Second, there are many factors, including aspecific symptoms, causing 195 
underdiagnosis of IEMs in neonates.[9] Third, despite our extensive and detailed search 196 
strategy, we cannot exclude that few references have been missed. The fact that after 197 
including the full text articles in the first round (n=91) new references still emerged via the 198 
reference lists of excluded and included full text articles emphasizes this once more. In order 199 
to optimize the search strategy, we conducted the second (n=44) and third (n=1) screening 200 
rounds. Fourth, in medical literature the definition of SID is not always applied consistently 201 
with regard to age ranges and clinical symptoms and signs. In an attempt to overcome this 202 
issue, we added the term “sudden unexpected death of infant” to our search strategy. Last, 203 
some included IEMs exemplify one protein deficiency in a large metabolic pathway involving 204 
many enzymes and transporters that potentially could cause a similar clinical picture. 205 
Therefore, we believe, based on our systematic review, that the IEMs included in Table 1 206 
should be considered as the minimal number of IEMs associated with SID and/or RS. Despite 207 
expanding NBS programs, clinical awareness needs to remain high amongst neonatologists 208 
and pediatricians as many IEMs have not been implemented in NBS programs. Early 209 
recognition of clinical presentations and subsequent diagnostic testing can possibly prevent 210 
fatal outcomes.[24] 211 
In summary, our systematic review identified the IEMs that are associated with RS 212 
and SID, a significant proportion of them being treatable disorders. Therefore in our opinion 213 
analysis of amino acids and acylcarnitines in blood/plasma/DBS and urine should be part of 214 
post-mortem diagnostic protocols, next to isolation of DNA and preferentially, material for 215 
functional tests such as analysis of cultured skin fibroblasts. To date, the combination of 216 
metabolite screening and DNA sequencing techniques would harbor the best of both methods, 217 
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Legends to tables and figures: 329 
Figure 1. Flowchart of detailed search strategy.  330 
Legend: CINAHL, Cochrane, Pubmed and Embase were searched using both MeSH terms 331 
and free text ("Metabolism, Inborn Errors"[Mesh] OR "inborn errors of metabolism" OR 332 
"mitochondrial fatty acid oxidation") AND ("Sudden Infant Death"[Mesh] OR "sudden infant 333 
of death" OR "sudden infant death syndrome" OR "unexpected death" OR "sudden 334 
unexpected death of infant" OR "Reye Syndrome"[Mesh]) AND (Humans[Mesh]) AND 335 
("Infant, Newborn, Child, Adolescent"[Mesh] OR newborn OR infant OR child). Search 336 
strategy was conducted on February, 15
th
 2013. Due to the elapsed time between the 337 
execution of the search strategy and the completion of the manuscript, the search strategy was 338 
repeated on August, 28
th
 2015, to screen for possible extra IEMs. This lead to the inclusion of 339 
only one additional IEM associated with either SIDS and/or RS: dihydrolipoamide 340 
dehydrogenase deficiency (DLD deficiency; MIM #246900). 341 
 342 
Table 1. The IEMs associated with either SID and/or RS.  343 
Legend: 
*
Dihydrolipoamide dehydrogenase deficiency (DLD deficiency; MIM #246900), 344 
#
Medium chain 3-ketoacyl-CoA thiolase deficiency (MCKAT deficiency; MIM #602199): 345 
these IEMs were not included in the list of the Society for the Study of Inborn Errors of 346 
Metabolism, but were found via the search strategy and therefore included as IEMs associated 347 
with either SID and/or RS. 
†
According to McHugh et al [17]; 
‡
according to Kishnani et al 348 
[18]; 
§
according to Gonzalez et al.[19] 
**
Reported to have caused clinical ascertainment 349 
and/or neonatal death before NBS test results were available.[6, 7, 10] 
||
Included in the 350 
expanded Dutch population NBS program since 2007.[25] 
¶
Recommended in 2015 for 351 
expansion of the Dutch population NBS program.[25] 352 
